X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BAT8006 is an innovative antibody drug conjugate targeting Folate Receptor α. It is being evaluated for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Lead Product(s): BAT8006
Therapeutic Area: Oncology Product Name: BAT8006
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
BAT6026 is a novel OX40 agonist antibody with enhanced antibody dependent cellular cytotoxicity. It is being evaluated in phase 1/2 clinical trials in combination with sodium chloride injection for the treatment of patients with moderate to severe atopic dermatitis.
Lead Product(s): Sodium Chloride
Therapeutic Area: Dermatology Product Name: BAT6026
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
FDA has approved Avzivi® (bevacizumab-tnjn), a biosimilar humanized monoclonal antibody that binds and inhibits VEGF, for the treatment for lung and colorectal cancers.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Avzivi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
BAT2206 (ustekinumab) is a Stelara-biosimilar, which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23. It is being evaluated for the treatment of Plaque Psoriasis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: BAT2206
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Tofidence (tocilizumab-bavi) is the first Actemra biosimilar approved in the United States for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: Tofidence
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2023
Details:
Under the agreement, Biomm will have exclusive rights to distribute and market BAT2206 (ustekinumab), a proposed biosimilar to Janssen’s Stelara, in Brazil for the treatment of active psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: BAT2206
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biomm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2023
Details:
BAT8007 is an antibody-drug conjugate (ADC) targeting Nectin-4 designed for the treatment of solid tumors. Nectin-4 is a validated drug target with one approved drug for the treatment of solid tumors and is a target of high interest for new drug discovery.
Lead Product(s): BAT8007
Therapeutic Area: Oncology Product Name: BAT8007
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
BAT8008 is an ADC targeting Trop2 designed for the treatment of solid tumors. Trop2, is a member of tumor associated calcium signal transduction protein family, which is related to the regulation of intracellular calcium concentration.
Lead Product(s): BAT8008
Therapeutic Area: Oncology Product Name: BAT8008
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
BAT8010 is an antibody-drug conjugate targeting HER2 designed for the treatment of solid tumors. HER2, a member of the EGFR, is overexpressed in a variety of solid tumors, plays an important role in tumor proliferation, invasion, metastasis, and poor prognosis of tumors.
Lead Product(s): BAT8010
Therapeutic Area: Oncology Product Name: BAT8010
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
BAT1806 (tocilizumab) is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. Product is approved for the treatment of RA, sJIA, and CRS.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: BAT1806
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
